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Administration of hepatocyte-speciﬁc N-acetylgalactosamine–
Stk25 antisense oligonucleotide (ASO) effectively amelio-
rated liver steatosis, inﬂammatory inﬁltration, and
nutritional ﬁbrosis in obese mice. We also observed pro-
tection against high-fat-diet–induced hepatic oxidative
stress and improved mitochondrial function with Stk25 ASO
treatment. Moreover, N-acetylgalactosamine–Stk25 ASO
suppressed lipogenic gene expression and acetyl-CoA
carboxylase protein abundance in the liver, providing
insight into the molecular mechanisms underlying repres-
sion of hepatic steatosis.
BACKGROUND & AIMS: Nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH) are emerging
as leading causes of liver disease worldwide. Currently, no
speciﬁc pharmacologic therapy is available for NAFLD/NASH,
which has been recognized as one of the major unmet medical
needs of the 21st century. Our recent studies in genetic mouse
models, human cell lines, and well-characterized patientcohorts have identiﬁed serine/threonine protein kinase (STK)
25 as a critical regulator of hepatic lipid partitioning and
NAFLD/NASH. Here, we studied the metabolic beneﬁt of liver-
speciﬁc STK25 inhibitors on NAFLD development and pro-
gression in a mouse model of diet-induced obesity.
METHODS: We developed a hepatocyte-speciﬁc triantennary
N-acetylgalactosamine (GalNAc)-conjugated antisense oligonu-
cleotide (ASO) targeting Stk25 and evaluated its effect on
NAFLD features in mice after chronic exposure to dietary
lipids.
RESULTS: We found that systemic administration of
hepatocyte-targeting GalNAc-Stk25 ASO in obese mice effec-
tively ameliorated steatosis, inﬂammatory inﬁltration, hepatic
stellate cell activation, nutritional ﬁbrosis, and hepatocellular
damage in the liver compared with mice treated with GalNAc-
conjugated nontargeting ASO, without any systemic toxicity or
local tolerability concerns. We also observed protection against
high-fat-diet–induced hepatic oxidative stress and improved
mitochondrial function with Stk25 ASO treatment in mice.
Moreover, GalNAc-Stk25 ASO suppressed lipogenic gene
expression and acetyl-CoA carboxylase protein abundance in
598 Cansby et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 3the liver, providing insight into the molecular mechanisms
underlying repression of hepatic steatosis.
CONCLUSIONS: This study provides in vivo nonclinical proof-
of-principle for the metabolic beneﬁt of liver-speciﬁc inhibi-
tion of STK25 in the context of obesity and warrants future
investigations to address the therapeutic potential of GalNAc-
Stk25 ASO in the prevention and treatment of NAFLD. (Cell Mol
Gastroenterol Hepatol 2019;7:597–618; https://doi.org/
10.1016/j.jcmgh.2018.12.004)
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Antisense Oligonucleotide Therapy.
See editorial on page 682.
onalcoholic fatty liver disease (NAFLD), deﬁned asAbbreviations used in this paper: 4-HNE, 4-hydroxynonenal; ACC,
acetyl-CoA carboxylase; ALT, alanine aminotransferase; ASGP, asia-
loglycoprotein; ASO, antisense oligonucleotide; ASOR, 125I-asialo-
orosomucoid; AST, aspartate transaminase; DHE, dihydroethidium;
GalNAc, N-acetylgalactosamine; mRNA, messenger RNA; NAFLD,
nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver disease
activity score; NASH, nonalcoholic steatohepatitis; PBS, phosphate-
buffered saline; PCNA, proliferating cell nuclear antigen; STK25,
serine/threonine protein kinase 25; TAG, triacylglycerol; TBARS, thio-
barbituric acid-reactive substance; WAT, white adipose tissue.
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2352-345X
https://doi.org/10.1016/j.jcmgh.2018.12.004Nthe presence of 5% of hepatic steatosis in the
absence of competing liver disease etiologies or signiﬁcant
alcohol consumption, is emerging as a leading cause of liver
disease worldwide. Current estimates indicate that one ﬁfth
of adults in the developed world have NAFLD.1 In a sub-
group of patients with NAFLD, the disease progresses to
nonalcoholic steatohepatitis (NASH), which in addition to
liver steatosis is deﬁned by the presence of hepatic
inﬂammation, ﬁbrosis, and cellular damage in the form of
ballooning and apoptosis. NAFLD contributes to the patho-
genesis of type 2 diabetes and cardiovascular disease, and
patients with NASH are also at high risk of developing
cirrhosis, liver failure, and hepatocellular carcinoma.2,3 To
date, there is no established validated therapy for NAFLD/
NASH, which is at least partly attributed to an incomplete
understanding of the underlying pathogenetic mechanisms
and, consequently, a lack of suitable targets.4
In the search for novel targets that regulate ectopic
lipid accumulation in the context of nutritional stress and
obesity, we identiﬁed serine/threonine protein kinase
(STK)25, a member of the sterile 20 kinase superfamily,5
as a critical regulator of NAFLD.6–10 We found that diet-
induced NAFLD is exacerbated in mice overexpressing
STK25,7,8 and is prevented in mice with reduced STK25
activity by genetic depletion or antisense oligonucleotide
(ASO) treatment.6,8,10 Furthermore, we have shown that
STK25 messenger RNA (mRNA) and protein levels
correlate with the severity of NASH in human liver, and
several common nonlinked single-nucleotide poly-
morphisms in the human STK25 gene are associated with
altered liver fat.8–10 Interestingly, we found that STK25
coats the surface of intrahepatocellular lipid droplets
both in human and mouse liver cells.7,9 Of note, STK25 is
broadly expressed6,11,12 and it also critically regulates
lipid partitioning in extrahepatic tissues. Thus, our pre-
vious studies have shown that Stk25 transgenic mice
show aggravated diet-induced lipid storage in skeletal
muscle, pancreas, and brown and white adipose tissue,
which is accompanied by exacerbated inﬂammatory
inﬁltration and nutritional ﬁbrosis in these tissues, and
the reciprocal phenotype is seen in Stk25-/- mice.6,13–15We also found that overexpression/depletion of STK25
results in increased/reduced atherogenesis susceptibility
in a mouse model of hypercholesterolemia.16
Because of the broad expression of STK25, our previous
experiments using mouse models in which STK25 is globally
overexpressed or depleted did not allow us to address
whether the impact of STK25 on liver lipid metabolism is
direct or secondary to the action of STK25 in extrahepatic
tissues. Here, we performed an in vivo nonclinical proof-of-
principle study to assess the effect of using the trianten-
nary N-acetylgalactosamine (GalNAc)-conjugated Stk25 ASO,
which results in targeted ASO delivery to hepatocytes, on
NAFLD development and progression in obese mice. The
results of this study show that reducing STK25 levels
selectively in hepatocytes effectively ameliorates progression
of liver steatosis, inﬂammation, ﬁbrosis, and cellular damage
in mice in the context of obesity, warranting further in-
vestigations of STK25 inhibitors as potential new-in-class
drug candidates for the treatment of NAFLD in human
beings.
Results
GalNAc Conjugation Improves the Liver Potency
of Stk25 ASO
Dosing with generation 2.5 ASOs is known to result in
broad systemic target reduction, without penetrating the
blood-brain barrier,17 whereas conjugation of ASOs with a
GalNAc moiety leads to efﬁcient and highly selective uptake
in hepatocytes.18 Here, we measured the in vivo efﬁcacy of
GalNAc-conjugated Stk25 ASO (hereafter referred to as
GalNAc-Stk25 ASO) in chow diet–fed mice treated twice
weekly for 4 weeks with total doses of 0.15, 0.5, 1.5, or 5.0
mg/kg/wk. At study termination, we observed a dose-
dependent reduction of hepatic Stk25 expression with
90% repression of the target mRNA at the high dose level
(5.0 mg/kg/wk) (Figure 1A). As expected, no reduction in
Stk25 mRNA was seen in skeletal muscle of GalNAc-Stk25
ASO-treated mice at any dose level (Figure 1B). Our previ-
ous studies have shown that treatment of chow-fed mice
with a corresponding unconjugated generation 2.5 Stk25
ASO (complementary to the identical 16-nucleotide intronic
region of the Stk25 gene; hereafter referred to as Stk25 ASO)
by similar regimen reduces hepatic Stk25 expression by
Figure 1. (A) Dose-
dependent reduction of
Stk25 mRNA expression
in the liver (B) but not in
the skeletal muscle from
chow-fed lean mice
treated with GalNAc-
Stk25 ASO for 4 weeks.
(C) Dose-response curves
of Stk25 ASO and Gal-
NAc-Stk25 ASO in chow-
fed mice. Data are
means ± SD (n ¼ 4 mice
per group) compared with
a control group of mice
dosed with PBS. *P < .05,
**P < .01.
2019 Stk25 ASO in Liver Protects Mice From NAFLD 59990% when using doses of 25–50 mg/kg/wk.10 The median
effective dose (ie, the effective dose required to reduce he-
patic Stk25 levels by 50%) was 0.2 mg/kg/wk for GalNAc-
Stk25 ASO and 2.3 mg/kg/wk for Stk25 ASO (Figure 1C).
Thus, GalNAc conjugation improved the potency of Stk25
ASO in the liver by approximately 10-fold, similar to that
observed with ASOs inhibiting other hepatocyte targets
in mice.18
Body weight, organ (liver, kidney, and spleen)
weights, and plasma chemistry parameters (albumin,
bilirubin, blood urea nitrogen, and creatinine) remained
within normal reference values in mice treated with
GalNAc-Stk25 ASO (Figure 2A–H). There was high intra-
individual variability in plasma alanine aminotransferase
(ALT) and aspartate transaminase (AST) measurements;
however, all values were in the normal range (ie, well
below 100 IU/L for ALT and 200 IU/L for AST), signifying
that the GalNAc-Stk25 ASO was well tolerated (Figure 2I
and J). We previously reported similar unremarkable
ﬁndings in terms of body and organ weights and blood
chemistry when using Stk25 ASO.10Suppression of Hepatic STK25 by GalNAc-Stk25
ASO Treatment Effectively Protects Against Liver
Steatosis, Macrophage Inﬁltration, Nutritional
Fibrosis, and Hepatocellular Injury in Obese Mice
To show preclinical proof-of-principle for GalNAc-Stk25
ASO therapy in repressing the progression of NAFLD, we
treated diet-induced obese mice with GalNAc-Stk25 ASO
(12.5 mg/kg/wk) and, for comparison, with parent Stk25
ASO (50 mg/kg/wk), twice weekly for 6 weeks. In addi-
tion, GalNAc-conjugated control ASO (12.5 mg/kg/wk),
which is a nontargeting ASO of the same length and
chemistry as GalNAc-Stk25 ASO, as well as the phosphate-
buffered saline (PBS)-treated group, were included in all
experiments (Figure 3). Consistent with previous experi-
ence with this class of ASOs,18 we found that treatment
with GalNAc-Stk25 ASO resulted in signiﬁcant repression
of STK25 levels in the liver, but not in skeletal muscle or
white adipose tissue (WAT), of high-fat–fed mice
(Figure 4). In contrast, treatment with unconjugated
parent Stk25 ASO resulted in signiﬁcant reduction of
Figure 2. Body and organ weights as well as plasma chemistry parameters in chow-fed lean mice dosed with PBS,
GalNAc-control ASO, or GalNAc-Stk25 ASO for 4 weeks. (A) Body weight. (B–D) Organ weights; values in control group of
mice dosed with PBS are set to 1. (E–J) Plasma chemistry. Data are means ± SD from 4 mice per group. BUN, blood urea
nitrogen; cntr, control. *P < .05.
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Figure 3. Schematic pre-
sentation of the experi-
mental design of the
in vivo proof-of-principle
study to assess the ef-
fect of using the GalNAc-
conjugated Stk25 ASO on
NAFLD development and
progression in obese
mice. Cntr, control.
2019 Stk25 ASO in Liver Protects Mice From NAFLD 601STK25 levels in all tissues examined (ie, in liver, skeletal
muscle, and WAT) (Figure 4).
Body weights were similar in all 4 groups of obese mice
(Figure 5A); however, food intake was not measured. We
observed no difference in general behavior or clinical signs
(body posture, mood, and motor activity) comparing the
high-fat–fed mice treated with Stk25-targeting ASOs vs the
control groups, and no local injection-site reactions were
recorded. Notably, we found that the homeostasis model
assessment score of insulin resistance was improved
signiﬁcantly in obese mice treated with GalNAc-Stk25 ASO
compared with the placebo group of mice (Figure 5B). To
study whether repression of STK25 levels induces the risk
of hepatocellular carcinoma development, we examined cell
proliferation in the liver samples collected from high-fat-
diet–fed mice in all 4 treatment groups. We did not detect
any increase in hepatic cell proliferation by immunoﬂuo-
rescence or Western blot analysis for commonly used pro-
liferation markers proliferating cell nuclear antigen (PCNA)
and Ki67 in mice dosed with Stk25 ASO or GalNAc-Stk25
ASO compared with mice treated with PBS or GalNAc-
control ASO (Figure 5C and D).
Chronic exposure to dietary lipids is known to promote
ectopic lipid storage and meta-inﬂammation in the liver.3
Consistently, we found that the livers of high-fat-diet–fed
mice treated with PBS or GalNAc-control ASO were visibly
lipid-laden with a milky pale appearance (Figure 6A). In
contrast, the livers from mice dosed with Stk25 ASO or
GalNAc-Stk25 ASO were dark red, similar to livers from lean
mice fed a regular chow diet (Figure 6A). Microscopic ex-
amination of H&E- and Oil Red O–stained liver sections alsoshowed pronounced steatosis in the 2 control groups of
mice, while the density and size of lipid droplets were
reduced markedly in mice dosed with Stk25 ASO or GalNAc-
Stk25 ASO (Figure 6A–C). Similarly, biochemical analysis
showed that the hepatic triacylglycerol (TAG) content was
signiﬁcantly lower in the liver extracts from both groups
receiving Stk25-targeting ASOs (Figure 6D). Notably, the
skeletal muscle TAG content was not altered in mice treated
with GalNAc-Stk25 ASO vs GalNAc-control ASO (4.8 ± 1.4 vs
5.0 ± 2.3 mg/mg of tissue, respectively).
Hepatic macrophages, which are critical inﬂammatory
mediators in the pathogenesis of NASH, can arise either
from circulating monocytes or from self-renewing local
macrophages, termed Kupffer cells.19 Both macrophage
populations are positive for F4/80, and monocyte-derived
macrophages also are characterized by high expression of
Gr1 (Ly6C).19 We found that Gr1 (Ly6C)- and F4/80-
positive area was reduced markedly in the livers from
mice treated with Stk25 ASO or GalNAc-Stk25 ASO
compared with mice in both control groups (Figure 7A–C).
In fact, we readily observed microgranulomatous lesions
and lipogranulomas in the livers from PBS- or GalNAc-
control ASO-treated mice (Figure 7D), but not in mice
dosed with Stk25 ASO or GalNAc-Stk25 ASO, consistent with
attenuation of hepatic macrophage inﬁltration by repression
of STK25. Furthermore, repression of STK25 abundance
protected from diet-induced perivenular/pericellular
ﬁbrosis as shown by staining with Picrosirius Red (stains
both collagen type I and type III) (Figure 8A) and immu-
noﬂuorescence analysis for collagen type I (Figure 8A and
B). Moreover, immunostaining for a-smooth muscle actin, a
Figure 4. Treatment of high-fat-diet–fed mice with GalNAc-Stk25 ASO markedly reduced hepatic STK25 levels. Mice
were treated with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or
placebo (PBS) for 6 weeks. (A) Hepatic Stk25 mRNA expression. (B–D) STK25 protein abundance in the (B) liver, (C) skeletal
muscle, and (D) WAT. Protein levels were analyzed by densitometry; representative Western blots are shown with pan-actin,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), or b-actin used as loading controls. (E) Representative liver sections
processed for immunoﬂuorescence with anti-STK25 antibody (red); nuclei were stained with DAPI (blue). Scale bars: 20 mm.
(A–D) Data are means ± SD (n ¼ 6–8 mice per group) compared with a control group of mice dosed with PBS. Cntr, control.
*P < .05, **P < .01.
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2019 Stk25 ASO in Liver Protects Mice From NAFLD 603marker for activated hepatic stellate cells responsible for
liver collagen deposition, similarly was reduced in the livers
from mice receiving Stk25-targeting ASOs (Figure 8A and C).Hepatic hydroxyproline content, a marker of collagen
deposition, also was lower in liver extracts from mice
treated with Stk25 ASO or GalNAc-Stk25 ASO (Figure 8D).
604 Cansby et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 3Consistent with suppression of hepatic macrophage
inﬁltration and collagen accumulation by GalNAc-Stk25 ASO
treatment, we found reduced mRNA expression of several
markers of inﬂammation and ﬁbrinogenesis in livers from
mice dosed with GalNAc-Stk25 ASO (Figure 9A and B).
Evidence of hepatocellular damage was readily observed
in the livers from control groups of mice, as shown by the
presence of apoptotic hepatocytes (detected by terminal
deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling assay [TUNEL]) and Mallory
bodies (shown by immunostaining for ubiquitin)
(Figure 10), as well as enlarged nuclei containing intra-
nuclear vacuoles and ballooning degradation of hepatocytes
(Figure 7D); we did not detect these features in mice
receiving Stk25 ASO or GalNAc-Stk25 ASO.Treatment With GalNAc-Stk25 ASO Reverses
Diet-Induced NAFLD in Mice
We assessed the liver histopathology in high-fat-diet–fed
mice by using the NAFLD activity score (NAS) and ﬁbrosis
scoring based on the Kleiner/Brunt criteria adapted to
rodents.20–24 Mice dosed with Stk25 ASO or GalNAc-Stk25
ASO scored signiﬁcantly lower both for NAS and ﬁbrosis
compared with mice receiving PBS or GalNAc-control ASO,
with the most pronounced improvement seen in the Gal-
NAc-Stk25 ASO-treated group (Figure 11A–C). Interestingly,
plasma ALT and AST levels, the most widely used clinical
biomarkers of NAFLD/NASH, were reduced signiﬁcantly in
obese mice treated with GalNAc-Stk25 ASO compared with
baseline values measured before initiation of ASO treatment,
suggesting that STK25 inhibition not only prevents but also
reverses diet-induced NAFLD (Figure 11D and E).Stk25 Targeting ASOs Reduce Oxidative
Stress and Improve Mitochondrial Function
in Mouse Liver
Oxidative stress plays a crucial role in NASH
progression.25 We found that the levels of 4-
hydroxynonenal (4-HNE), an end-product of peroxidation
of membrane N-6-polyunsaturated fatty acids and consid-
ered a reliable biomarker of oxidative liver damage, and the
dye dihydroethidium (DHE), which detects superoxide
radicals (O2
$ –), were signiﬁcantly lower in the livers from
obese mice treated with Stk25-targeting ASOs compared
with mice in the control groups (Figure 12A–C). Moreover,
we observed suppressed thiobarbituric acid-reactiveFigure 5. (See previous page). Treatment with GalNAc-Stk2
proliferation in mice fed a high-fat diet, whereas the whole-b
GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk),
weeks. (A) Body weight curves; the number of weeks on a high
high-fat diet feeding). (B) The homeostasis model assessment s
following equation: fasting glucose (mg/dL)  fasting insulin (
immunoﬂuorescence with anti-PCNA (pink) or anti-Ki67 antibod
section of reactive lymph node (T2235161-3; Gentaur, Brussel
staining. Scale bars: 40 mm. (D) Liver protein lysates were analyze
Protein levels were analyzed by densitometry; representative
control. (A, B, and D) Data are means ± SD from 6–8 mice persubstance (TBARS) content, a classic marker of lipid per-
oxidation, in the liver extracts from mice dosed with Stk25
ASO or GalNAc-Stk25 ASO (Figure 12D).
Several lines of evidence suggest that mitochondrial
dysfunction, and activation of an alternative extra-
mitochondrial fatty acid oxidation pathway in peroxisomes,
are the leading mechanisms that promote hepatic oxidative
stress.3,25–27 Interestingly, we found that staining with
MitoTracker Red, a ﬂuorescent dye that speciﬁcally accu-
mulates within respiring mitochondria, was approximately
3-fold higher in the liver sections from mice treated with
Stk25-targeting ASOs compared with mice in the control
groups (Figure 12A and E). Consistently, we found that the
rate of b-oxidation was increased signiﬁcantly in primary
hepatocytes isolated from naive mice of the same strain,
when treated in vitro with GalNAc-Stk25 ASO vs GalNAc-
control ASO (42.0 ± 9.2 vs 26.4 ± 5.0 pmol/min/mg,
respectively; P < .01). Reciprocally, immunostaining for
peroxisome biogenesis marker PEX5 was approximately
2.5-fold lower in the livers from mice dosed with Stk25 ASO
or GalNAc-Stk25 ASO compared with PBS or GalNAc-control
ASO (Figure 12A and F).
Suppression of Lipogenic Gene Expression
and Acetyl-CoA Carboxylase Protein
Abundance in Livers From Mice Treated With
GalNAc-Stk25 ASO
Because the treatment with Stk25-targeting ASOs effec-
tively protected against hepatic steatosis, we examined the
expression of a set of genes involved in lipogenesis in the
livers from all 4 groups of high-fat–fed mice. We found that
the hepatic mRNA levels of Acc1 and Acly controlling de
novo fatty acid synthesis, as well as Gpam and Hmgcr
regulating TAG and cholesterol biosynthesis, respectively,
were down-regulated by approximately 2- to 3-fold in the
livers from mice treated with GalNAc-Stk25 ASO (Figure 9C).
Interestingly, although the expression of Gpam was lower in
mice treated with both Stk25-targeting ASOs compared with
both control groups, the mRNA levels of Acc1, Acly, and
Hmgcr were reduced only in the livers from GalNAc-Stk25
ASO-treated mice (Figure 9C), providing a likely mechanism
for the improved efﬁcacy of GalNAc-conjugated Stk25 ASO in
suppressing hepatic lipid accumulation compared with un-
conjugated parent Stk25 ASO. Next, we examined the
expression of enzymes regulating hepatic lipid oxidation.
From the rate-limiting enzymes studied, only the mRNA
expression of Acc2, which represses lipid oxidation through5 ASO had no impact on body weight gain or liver cell
ody insulin sensitivity was improved.Mice were treated with
GalNAc-control ASO (12.5 mg/kg/wk), or placebo (PBS) for 6
-fat diet is shown (the treatment was initiated at week 15 of
core of insulin resistance (HOMA-IR) was calculated using the
ng/mL)/405. (C) Representative liver sections processed for
ies (pink); nuclei were stained with DAPI (blue). A histologic
s, Belgium) was used as positive control for PCNA and Ki67
d by Western blot using antibodies speciﬁc for PCNA or Ki67.
Western blots are shown with pan-actin used as a loading
group. Cntr, control. *P < .05, BP ¼ .052.
Figure6. GalNAc-Stk25ASO
treatment ameliorated liver
steatosis in obese mice.
Mice were treated with Gal-
NAc-Stk25 ASO (12.5 mg/kg/
wk), Stk25 ASO (50 mg/kg/
wk), GalNAc-control ASO
(12.5 mg/kg/wk), or placebo
(PBS) for 6 weeks. (A) Repre-
sentative images of whole
liver; representative liver sec-
tions stained with H&E or Oil
Red O for lipids. (B) Repre-
sentative liver sections
stained with H&E from age-
matched chow diet–fed lean
mice as well as Stk25
knockout mice and their wild-
type littermates fed a high-fat
diet. Stk25 knockout mice
were a gift from B. Howell
(State University of New York
Upstate Medical University,
Syracuse, NY). (C) Quantiﬁca-
tion of total lipid area in
liver sections. (D) TAG content
in liver extract. (C and D)
Dataaremeans±SDfrom6–8
mice per group. Scale bars:
100 mm. CD, chow diet; cntr,
control; HFD, high-fat diet;
KO, knockout; WT, wild-type.
*P < .05, **P < .01.
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Figure 7. Treatment with GalNAc-Stk25 ASO protected against high-fat-diet–induced liver inﬂammation in mice. Mice
were treated with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or
placebo (PBS) for 6 weeks. (A) Representative liver sections processed for immunoﬂuorescence with anti-Gr1 (Ly6C) (pink) or
anti-F4/80 antibodies (green); nuclei were stained with DAPI (blue). Scale bars: 25 mm for Gr1 (Ly6C) and 12.5 mm for F4/80. (B
and C) Quantiﬁcation of (B) Gr1 (Ly6C) and (C) F4/80 staining. (D) H&E-stained liver sections of mice dosed with GalNAc-
control ASO showing the presence of microgranuloma and lipogranuloma, enlarged nuclei containing intranuclear vacuoles,
and hepatocellular ballooning. Scale bars: 100 mm. (B and C) Data are means ± SD from 7–8 mice per group. Cntr, control.
*P < .05, **P < .01.
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Figure 8. Administration of GalNAc-Stk25 ASO effectively reduced nutritional ﬁbrosis in obese mice. Mice were treated
with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or placebo (PBS)
for 6 weeks. (A) Representative liver sections stained with Picrosirius Red or processed for immunoﬂuorescence with
anti–collagen I (green) or anti–a-smooth muscle actin (a-SMA) antibodies (yellow); nuclei were stained with DAPI (blue). Scale
bars: 100 mm for Picrosirius Red, 12.5 mm for collagen I, and 50 mm for a-SMA. (B and C) Quantiﬁcation of (B) collagen I and (C)
a-SMA staining. (D) Hydroxyproline content in liver extract. (B–D) Data are means ± SD from 6–8 mice per group. Cntr, control.
*P < .05, **P < .01.
2019 Stk25 ASO in Liver Protects Mice From NAFLD 607allosteric inhibition of mitochondrial fatty acid transporter
carnitine palmitoyltransferase 1 (CPT1),28 was altered
signiﬁcantly in the livers from mice dosed with GalNAc-
Stk25 ASO (approximately 1.5-fold lower compared with
controls) (Figure 9D).
Consistent with our ﬁnding of reduced mRNA expression
of Acc1/2, the total protein level of acetyl-CoA carboxylase
(ACC) was 2.0- ± 1.0-fold lower in the livers from high-
fat–fed mice treated with GalNAc-Stk25 ASO compared withGalNAc-control ASO (Figure 13A). The ratio of phospho-ACC
(inactive form)/ACC was not altered signiﬁcantly in
comparing these 2 groups (Figure 13A).STK25 Is Activated in the Liver by Starvation and
Challenge With a High-Fat Diet
The phosphorylation level of the threonine 174 residue
of STK25 has been shown to adequately reﬂect the activity
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Figure 10. Apoptotic hepatocytes (detected by terminal deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling [TUNEL] assay) and Mallory bodies (shown by immunostaining for ubiquitin black
arrows) were readily observed in the livers from control groups of high-fat–fed mice, but not in mice receiving Stk25
ASO (50 mg/kg/wk) or GalNAc-Stk25 ASO (12.5 mg/kg/wk). Representative liver sections stained with TUNEL or processed
for immunohistochemistry with anti-ubiquitin antibody (brown). Scale bars: 100 mm. Cntr, control.
2019 Stk25 ASO in Liver Protects Mice From NAFLD 609of this kinase.29 Notably, we and other research groups
previously have shown that inﬂammatory and oxidative
stress increase the threonine 174 phosphorylation of STK25
in several different cell types in vitro11,29; however, the
physiological upstream activators of this kinase in vivo
remain elusive. Interestingly, we found that starvation and
challenge with a high-fat diet, which both lead to a shift in
fuel metabolism from carbohydrates to fat and increase
oxidative stress parameters, markedly and signiﬁcantly
increased the threonine 174 phosphorylation of STK25 in
mouse liver (Figure 13B and C).Discussion
This study found that systemic administration of
hepatocyte-targeting GalNAc-conjugated Stk25 ASO in obese
mice effectively ameliorated high-fat-diet–induced steatosis,
inﬂammatory inﬁltration, hepatic stellate cell activation,
nutritional ﬁbrosis, and hepatocellular damage in the liver
compared with mice treated with GalNAc-conjugated non-
targeting ASO, without any changes in total body weight
(Figure 14). The GalNAc-Stk25 was well tolerated in mice
and we observed no systemic toxicity or local tolerability
concerns.
Our previous experiments have shown that inhibiting
STK25 by treatment with unconjugated parent ASO (ie,
the generation 2.5 Stk25 ASO), which also was used as an
internal control in this study, prevents NAFLDFigure 9. (See previous page).Measurement of mRNA expres
and (B) ﬁbrosis, as well as genes controlling (C) lipid synthe
Mice were treated with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk
or placebo (PBS) for 6 weeks. Relative mRNA expression was a
Data are means ± SD (n ¼ 6–8 mice per group) compared with a
**P < .01.progression in obese mice.10 Generation 2.5 ASOs, which
distribute broadly to peripheral organs including liver,
muscle, and adipose tissue,17 have been widely used in
preclinical experimental models30–33 and currently are
being evaluated in various clinical trials.32,34 In contrast,
conjugation of an ASO with a GalNAc moiety, as was
applied in this study, targets the ASO selectively to the
liver via the GalNAc-binding asialoglycoprotein (ASGP)
receptor, a highly conserved C-type lectin that is
expressed abundantly on hepatocytes.18 GalNAc-
conjugated ASOs recently have advanced into preclinical
and clinical development and the results of early clinical
trials evaluating target reduction and safety have been
reported for 4 of these ASOs.35 In line with previously
published observations for different targets,18,36 we here
found that conjugation of a GalNAc cluster improved the
efﬁcacy of parent unconjugated ASO in repressing Stk25
levels in the mouse liver by approximately 10-fold.
Furthermore, we found that treatment with GalNAc-Stk25
ASO achieved superior or similar efﬁcacy in reducing diet-
induced liver steatosis, inﬂammation, and ﬁbrosis in mice
compared with using 4-fold higher doses of parent un-
conjugated Stk25 ASO by an identical administration
scheme (6 weeks of treatment fractionated into 2 weekly
injections). Thus, this study provides in vivo evidence that
repression of STK25 levels selectively in hepatocytes is
sufﬁcient for the metabolic beneﬁt in ameliorating diet-
induced NAFLD.sion of selected genes related to (A) hepatic inﬂammation
sis and (D) oxidation in the livers from high-fat–fed mice.
25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk),
ssessed by quantitative real-time polymerase chain reaction.
control group of mice dosed with PBS. Cntr, control. *P < .05,
Figure 11. Treatment with GalNAc-Stk25 ASO reversed high-fat-diet–induced NAFLD in mice. Mice were treated with
GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or placebo (PBS) for 6
weeks. (A and B) Quantiﬁcation of NAS based on 3 histologic features (steatosis, 0–3; inﬂammation, 0–3; hepatocellular
ballooning, 0–2) in H&E-stained liver sections. (C) Quantiﬁcation of ﬁbrosis score based on the Kleiner/Brunt criteria adapted to
rodents (0, no ﬁbrosis; 1, focal pericellular ﬁbrosis in zone 3; 2, perivenular and pericellular ﬁbrosis conﬁned to zones 2 and 3;
3, bridging ﬁbrosis; and 4, cirrhosis) in liver sections stained with Picrosirius Red. (D and E) Activity of plasma ALT and AST
expressed as the ratio of values measured after vs before the treatment in each group. Data are means ± SD from (A–C) 6 mice
per group or (D and E) 4 mice per group. Cntr, control. *P < .05, **P < .01.
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perior effect in obese mice compared with unconjugated
parent ASO (Stk25 ASO) in reducing hepatic steatosis and
inﬂammation measured by NAS scoring of H&E-stained liver
sections. In contrast, no difference was detected in hepatic
lipids or inﬂammatory inﬁltration in mice treated with Gal-
NAc-Stk25 ASO vs Stk25 ASO by biochemical measurement of
TAG content or assessment of Gr1 (Ly6C)- and F4/80-positive
areas in liver, respectively, although a marked and statistically
signiﬁcant improvement was observed in both groups of mice
receiving Stk25-targeting ASOs compared with the control
groups (ie, treatment with PBS or nontargeting control ASO).
Furthermore, we observed a signiﬁcant improvement in his-
tologic ﬁbrosis score assessed in Picrosirius Red–stained liversections with GalNAc-Stk25 ASO vs Stk25 ASO treatment,
although both of these ASOs had similar effects on reducing
hepatic ﬁbrosis based on measurements of the collagen
I–positive area and hydroxyproline content. Notably, although
the same cohort of mice was used in all of these assessments,
different regions of the liver were collected for diverse types
of analyses: NAS and ﬁbrosis scoring was performed on
parafﬁn sections, immunoﬂuorescence analysis of macrophage
markers and collagen I was conducted on frozen sections,
whereas TAG and hydroxyproline content was measured in
liver homogenate by biochemical assays. Importantly, zonation
of glucose and fatty acid metabolism has been reported in the
liver lobules according to proximity to the portal triad, such
that hepatocytes closest to the portal vein (periportal or zone
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Figure 13. Downstream targets and upstream activators of STK25. (A) Liver protein lysates from high-fat–fed mice treated
with GalNAc-Stk25 ASO vs GalNAc-control ASO (12.5 mg/kg/wk) were analyzed by Western blot using antibodies speciﬁc for
total ACC or phospho-ACC (Ser79), with pan-actin used as a loading control. (B and C) Liver lysates were collected from male
C57BL/6J mice (B) fed a normal chow diet and fasted for 12 hours vs re-fed or (C) fed a normal chow diet vs a high-fat diet for
18 weeks. The lysates were immunoprecipitated with anti-STK25 antibody and analyzed by Western blot using antibodies
speciﬁc for total STK25 or phospho-threonine. Immunoprecipitation of liver lysates from Stk25 knockout mice was included as
a negative control. Protein levels were analyzed by densitometry and data are shown as the total and phospho-protein
abundance, as well as the ratio of phospho-protein to total protein. Representative Western blots are shown. Data are
means ± SD from 6–8 mice per group. Cntr, control. *P < .05.
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oxidation, whereas glycolysis and lipogenesis occur at a higher
rate in hepatocytes closest to the central vein (pericentral or
zone 3).37–39 As a consequence, lipids, inﬂammation, and he-
patocellular damage are distributed differentially within the
liver lobules, and steatosis in adult NAFLD and oxidative
damage to cells in NASH are localized chieﬂy to pericentral
regions.37,38 Thus, metabolic zonation of the liver might have
contributed to the differences in results observed in this study
comparing diverse types of assessments.Figure 12. (See previous page). Stk25-targeting ASOs efﬁc
chondrial activity in the livers of obese mice. Mice were trea
mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or placebo (P
for immunohistochemistry/immunoﬂuorescence with anti–4-HNE
(red) or MitoTracker Red (red); nuclei were stained with DAPI (bl
and 12.5 mm for PEX5. (B and D) Quantiﬁcation of (B) 4-HNE add
of (C) DHE, (E) MitoTracker Red, and (F) PEX5 staining. (B–F) Dat
.05, **P < .01, BP ¼ .087.Notably, zonal heterogeneity of the ASGP receptor has
been reported previously even if the results are not fully
consistent. Autoradiography analysis of rat livers perfused
ex vivo with the ligand 125I-asialo-orosomucoid (ASOR)
showed a higher uptake by the ASGP receptor in zone 3
than in zone 1 hepatocytes.40 In contrast, McFarlane et al41
found that the binding of antibodies to the ASGP receptor
was higher in periportal areas in the rat liver. When peri-
portal and perivenous parenchymal cells were isolated from
rat livers and incubated in vitro with ASOR, the maximumiently suppressed oxidative stress and improved mito-
ted with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50
BS) for 6 weeks. (A) Representative liver sections processed
(brown) or anti-PEX5 antibodies (green), or stained with DHE
ue). Scale bars: 50 mm for 4-HNE, DHE, and MitoTracker Red,
ucts and (D) TBARS in liver extract. (C, E, and F) Quantiﬁcation
a are means ± SD from 6–8 mice per group. Cntr, control. *P <
Figure 14. Schematic illustration of metabolic responses in the liver from mice treated with GalNAc-Stk25 ASO vs
GalNAc-control ASO. Treatment with hepatocyte-speciﬁc GalNAc-conjugated Stk25 ASO effectively ameliorated high-fat-
diet–induced liver steatosis, inﬂammatory inﬁltration, hepatic stellate cell (HSC) activation, nutritional ﬁbrosis, and hepato-
cellular damage compared with mice treated with GalNAc-conjugated nontargeting ASO, without any systemic toxicity or local
tolerability concerns.
2019 Stk25 ASO in Liver Protects Mice From NAFLD 613binding capacity of the ASGP receptor on periportal cells
was found to be 0.70 times that of perivenous cells.42
Furthermore, injection of a small amount of ASOR in vivo
showed that in young rats binding and uptake occurred
predominantly in the periportal area, whereas in older rats
a homogeneous distribution over the periportal and peri-
venous zones was observed.43 In this study, we have not
attempted to systematically analyze the intrahepatic dis-
tribution pattern of GalNAc-Stk25 ASO; however, previous
reports showing that ASGP-receptor–dependent uptake
pathways are under zonal control suggest the possibility of
zonal differences in the repression of STK25 levels by Gal-
NAc-Stk25 ASO.
Mechanistically, we found decreased mRNA and protein
abundance of ACC in the livers from obese mice dosed with
GalNAc-Stk25 ASO vs GalNAc-control ASO. This alteration is
expected to reprogram hepatic metabolism, leading to
reduced lipid synthesis and increased mitochondrial
b-oxidation.44 These data also conﬁrm our previous ﬁndings
of lower hepatic ACC levels in Stk25 knockout mice as well
as in mice treated with generation 2.5 Stk25 ASOs.6,10Notably, several lines of evidence suggest that decreases
in mitochondrial functionality, with subsequent increases in
oxidative stress, are the leading upstream triggers in tran-
sitioning from benign liver steatosis to NASH.25,26 Here, we
observed that treatment with Stk25-targeting ASOs pro-
tected against liver oxidative damage, as evidenced by
reduced levels of hepatic 4-HNE, DHE, and TBARS (classic
markers of oxidative stress), and improved mitochondrial
function, as evidenced by enhanced MitoTracker Red
staining, compared with the control groups of mice.
Consistent with these ﬁndings, we previously have reported
protection against methionine- and choline-deﬁcient diet-
induced oxidative stress, as well as functional and ultra-
structural impairment in mitochondria, in the livers from
Stk25-/- mice compared with wild-type littermates.8
In this study, NAFLD was induced in mice by high-fat
diet (45 kcal% fat) feeding for 21 weeks. Most of our pre-
vious work characterizing the whole-body function of
STK25, as well as its function in other organs such as
skeletal muscle, adipose tissue, and pancreas, has been
performed using this dietary regimen in genetically
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best basis for comparisons of the metabolic effects of STK25
in different organ systems. Still, using a single mouse model
is considered to be a limitation of the work and dosing with
GalNAc-Stk25 ASO in a different animal model of NAFLD/
NASH would be of high interest to provide further evidence
for its efﬁcacy. Furthermore, the detailed toxicology screens
(beyond the reported liver/kidney function tests and mea-
surement of organ/body weights in chow-fed lean mice and
monitoring the behavior/clinical signs and local injection-
site reactions in high-fat–fed mice) have not yet been per-
formed with GalNAc-Stk25 ASO.
In summary, GalNAc conjugation of Stk25 ASO provided
liver-speciﬁc delivery and markedly increased ASO potency
in reducing the hepatic target mRNA expression in mice
without any safety concerns. Treatment with GalNAc-Stk25
ASO ameliorated the development and progression of high-
fat-diet–induced NAFLD in a mouse model with the effect
being similar to, or improved, compared with 4-fold higher
doses of unconjugated Stk25 ASO, which results in broad
systemic target reduction. With multiple GalNAc-conjugated
ASOs advancing to late stage (phase 2b and phase 3) clinical
trials in different therapeutic areas, understanding of the
performance of this specialized class of ASOs is expected to
broaden in the next few years. With prevention and treat-
ment of NAFLD/NASH remaining a signiﬁcant unmet med-
ical need, future investigations to address the therapeutic
potential of GalNAc-Stk25 ASO are warranted.
Materials and Methods
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Generation of ASOs
The oligonucleotides used in this study were 16 nucle-
otides in length and chemically modiﬁed with phosphor-
othioates in the backbone, 3 of the 2’-4’ constrained ethyl
residues at each terminus, and a central deoxynucleotide
region of 10 residues (3-10-3 gapmer design). Oligonucle-
otides were synthesized as previously described.45 For
hepatocyte-targeting ASO, conjugation to GalNAc was per-
formed as previously described.46 ASO sequences used in
this study were as follows: Stk25 ASO 5’-GCA-
TAATCCCCTAGGC-3’ and control ASO 5’-GGCCAA-
TACGCCGTCA-3’. ASOs were dissolved in PBS (without Ca2þ
or Mg2þ; Invitrogen, Carlsbad, CA) for in vivo experiments.
Animal Experiments
Male C57BL/6J mice (Charles River, Sulzfeld, Germany;
Jackson, Sacramento, CA) were housed 4–8 per cage in a
temperature-controlled (21C) facility with a 12-hour light-
dark cycle with free access to water and food. To compare
the efﬁcacy of GalNAc-Stk25 ASO with parent unconjugated
Stk25 ASO in reducing the target gene expression, 6-week-
old mice fed a regular chow diet were administered GalNAc-
Stk25 ASO, Stk25 ASO, GalNAc-control ASO, or PBS twice
weekly for 4 weeks at the indicated total weekly concen-
trations by subcutaneous injections. At the age of 10 weeks,the mice were killed. Liver and skeletal muscle samples
were snap-frozen in liquid nitrogen and stored at -80C for
analysis of Stk25 mRNA expression.
To assess the metabolic effect of GalNAc-Stk25 ASO in
comparison with Stk25 ASO, 6-week-old mice were fed a
high-fat diet (45 kcal% fat; D12451; Research Diets, New
Brunswick, NJ) for 21 weeks and were treated with GalNAc-
Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk),
GalNAc-control ASO (12.5 mg/kg/wk), or placebo (PBS) by
intraperitoneal injections twice weekly for the last 6 weeks
(Figure 3). Body weight was recorded weekly during the
treatment period. At the age of 27 weeks, the mice were
killed after 4 hours of food withdrawal. Blood was collected
by heart puncture for analysis of ALT and AST activity and
glucose and insulin levels. Liver samples were collected for
histologic analysis (see later). Liver, gastrocnemius skeletal
muscle, and subcutaneous WAT samples also were snap-
frozen in liquid nitrogen and stored at -80C for biochem-
ical assays and/or analysis of gene and protein expression.
Based on the SD of the percentage change in Stk25mRNA
expression observed in chow-fed lean mice by Stk25 ASO
treatment in our previous study,10 we estimated that 4 mice
per group were required to have 80% power to detect a
60% reduction in target gene expression using a 2-sided
test with a 0.05 signiﬁcance level. Therefore, n ¼ 4 mice
per group were included in studies of Stk25 mRNA levels in
lean mice. Our previous experience dictated that larger
numbers generally are required to show pharmacologic ef-
fects in disease models owing to higher animal-to-animal
variability. Therefore, in most of the efﬁcacy assessments
performed in high-fat-diet–fed mice, 6–8 mice per treatment
group were included.
All animal experiments were performed after prior
approval from the local Ethics Committee for Animal Studies
at the Administrative Court of Appeals in Gothenburg,
Sweden, or by the Institutional Animal Care and Use Com-
mittee, Carlsbad, CA, following appropriate guidelines.Biochemical Assays
In chow-fed mice, plasma albumin, bilirubin, blood urea
nitrogen, creatinine, ALT, and AST levels were measured
using the AU480 Clinical Chemistry Analyzer (Beckman
Coulter, Providence, RI). In high-fat–fed mice, plasma ALT
and AST activity was measured using the ALT Activity Assay
Kit (700260; Cayman Chemical, Ann Arbor, MI) and the AST
Activity Assay Kit (MAK055; Sigma-Aldrich, St. Louis, MO),
respectively. Fasting blood glucose and plasma insulin were
assessed using the Accu-Chek glucometer (Roche Di-
agnostics, Basel, Switzerland) and the Ultrasensitive Mouse
Insulin Enzyme-Linked Immunosorbent Assay Kit (90080;
Crystal Chem, Downers Grove, IL), respectively. TAG and
collagen content were assessed in liver homogenate using
the Triglyceride Quantiﬁcation Colorimetric Kit (K622-100;
BioVision, Mountain View, CA) and the Hydroxyproline
Colorimetric Assay Kit (MAK008; Sigma-Aldrich), respec-
tively. To characterize hepatic oxidative stress, 4-HNE and
TBARS levels in liver homogenate were measured with the
OxiSelect HNE Adduct Competitive Enzyme-Linked
2019 Stk25 ASO in Liver Protects Mice From NAFLD 615Immunosorbent Assay Kit (STA-838; Cell Biolabs, Inc, San
Diego, CA) and the Lipid Peroxidation Assay Kit (MAK085;
Sigma-Aldrich), respectively.
Histology
Liver samples were ﬁxed with 4% (vol/vol) phosphate-
buffered formaldehyde (Histolab Products, Gothenburg,
Sweden), embedded in parafﬁn, sectioned, and stained with
H&E. Ten randomly selected microscopic ﬁelds (200) per
mouse were assessed for NAS according to the Kleiner/
Brunt criteria.20–23 To estimate the degree of ﬁbrosis, liver
sections were stained with Picrosirius Red (Histolab Prod-
ucts) and counterstained with Fast Green (Sigma-Aldrich);
10 randomly selected microscopic ﬁelds (200) per mouse
were assessed for ﬁbrosis score according to the Kleiner/
Brunt criteria.20,21,24 Apoptotic cells were detected by ter-
minal deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling assay with the Apo-BrdU-IHC
In Situ DNA Fragmentation Assay Kit (K403-50; BioVision).
In parallel, liver samples were embedded in optimal
cutting temperature mounting medium (Histolab Products)
and frozen in liquid nitrogen, followed by cryosectioning
and staining with Oil Red O (Sigma-Aldrich) for neutral
lipids. The total hepatic lipid area was quantiﬁed in Oil Red
O–stained sections in 5 randomly selected microscopic
ﬁelds (200) per mouse using ImageJ software (ImageJ
version 1.47; Wayne Rasband National Institutes of Health,
Bethesda, MD). Cryosections also were stained with DHE
(Life Technologies, Grand Island, NY) to assess oxidative
stress or MitoTracker Red (Thermo Fisher Scientiﬁc, Wal-
tham, MA) for the detection of respiring mitochondria as
previously described.8 The stained area was quantiﬁed in 5
randomly selected microscopic ﬁelds (200) per mouse
using ImageJ software.
The NAS and ﬁbrosis scoring was performed in a blinded
fashion by an independent observer; the other analyses
were not blinded to treatment allocation.
Immunohistochemistry and Immunoﬂuorescence
Liver sections were incubated with primary antibodies,
followed by incubation with biotinylated secondary anti-
bodies. The following primary antibodies were used: anti-
STK25 (YSK1; sc-6865; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-PCNA (MA5-1158; Invitrogen), anti-Ki67 (14-
5698-82; Invitrogen), anti-Gr1 (Ly6C) (ab15627; Abcam,
Cambridge, UK), anti-F4/80 (MCA497GA; Bio-Rad, Hercules,
CA), anti–collagen I (SAB4500362; Sigma-Aldrich), anti–a-
smooth muscle actin (ab5694; Abcam), anti–4-HNE (sc-
130083; Santa Cruz Biotechnology), anti-PEX5 (PA5-58716;
Invitrogen), and anti-ubiquitin (ab411; Abcam). For immu-
nohistochemical detection, anti-goat IgG (E0466; Dako,
Glostrup, Denmark) and anti-mouse IgG (E0464; Dako)
secondary antibodies were used, followed by horseradish-
peroxidase–conjugated streptavidin (P0397; Dako) and
diaminobenzidine staining (K3467; Dako). For immunoﬂu-
orescence detection, Alexa Fluor-594–labeled goat anti-rat
IgG (A11007; Invitrogen), Alexa Fluor-488–labeled rabbit
anti-mouse IgG (A11059; Invitrogen), Alexa Fluor-594–labeled donkey anti-goat IgG (A11058; Invitrogen), and
Alexa Fluor-594–labeled donkey anti-rabbit IgG (A21207;
Invitrogen) secondary antibodies were used. The stained
area was quantiﬁed in 5 randomly selected microscopic
ﬁelds (200) per mouse using ImageJ software.
Immunoprecipitation
For immunoprecipitation, 100 mg of protein from mouse
liver lysate was incubated overnight at 4C with 2 mg of anti-
STK25 antibody (25821-1-AP; Proteintech, Chicago, IL)
coupled with G-coupled Dynabeads (Invitrogen). Immuno-
precipitated protein samples were subjected to Western
blot (see later).
Quantitative Real-Time Polymerase Chain
Reaction and Western Blot Analysis in Mouse
Tissue Samples
RNA was isolated from the liver and skeletal muscle
samples with either the EZNA Total RNA Kit (R6834; Omega
Bio-Tek, Norcross, GA) or the RNeasy 96 Kit (74182; Qiagen,
Hilden, Germany) according to the manufacturer’s recom-
mendations, and complementary DNA was synthesized for
real-time polymerase chain reaction using the High-Capacity
Complementary DNA Reverse Transcription Kit (4368814;
Thermo Fisher Scientiﬁc). Relative quantiﬁcation was per-
formed with the QuantStudio 6 Flex System (Applied Bio-
systems, Foster City, CA) using complementary DNA or the
StepOnePlus Real-Time Polymerase Chain Reaction System
(Applied Biosystems) using total RNA (see Table 1 for
custom-designed primer and probe sequences). Relative
quantities of target transcripts were calculated after
normalization of the data to the endogenous control, 18S
ribosomal RNA (Applied Biosystems), or to total RNA
measured by the Quant-iT RiboGreen RNA reagent (Molec-
ular Probes, Eugene, OR).
Western blot on tissue samples was performed as pre-
viously described.47 The detection of speciﬁc proteins used
the following primary antibodies: anti-STK25, anti-PCNA,
anti-Ki67, anti-ACC (#3662; Cell Signaling Technology,
Boston, MA), anti–phospho-ACC (Ser79; #3661; Cell
Signaling Technology), anti–phospho-threonine (13-9200;
Invitrogen), anti–pan-actin (sc-8432; Santa Cruz Biotech-
nology), anti–glyceraldehyde-3-phosphate-dehydrogenase
(MA5-15738; Invitrogen), anti–b-actin (ab8226; Abcam),
and horseradish-peroxidase–conjugated secondary anti-
bodies anti-rabbit IgG (#7074; Cell Signaling Technology),
anti-mouse IgG (#7076; Cell Signaling Technology), anti-rat
IgG (#7077; Cell signaling Technology), and VeriBlot for IP
Detection Reagent (ab131366; Abcam).
Measurement of b-Oxidation in Mouse Primary
Hepatocytes
Primary hepatocytes were isolated using a collagenase
perfusion method,48 pooled from 4 C57BL/6J mice, and
seeded on 6-well plates (Nunc, Roskilde, Denmark) at a
density of 5  105 cells/well. The cells were cultured in
Williams E medium (Invitrogen) supplemented with 0.28
Table 1.Sequences of Custom-Designed Primers and
Probes Used for Quantitative Real-Time Polymerase
Chain Reaction
Gene Sequence (5’-3’)
Stk25
Forward ATCAAGCAGTCGGCCTATGACT
Reverse CCTTGGCCAGCTCAATGG
Probe CAAGGCTGACATCTGGTCCCTGGG
F4/80
Forward CAAGGACACGAGGTTGCTGA
Reverse CAAGGGGCCAATCTGGAA
Probe TGCTCCTGGGTGCTGGGCATT
Ccl2
Forward TGGCTCAGCCAGATGCAGT
Reverse GGACACCTGCTGCTGGTGAT
Probe TGAGTAGCAGCAGGTGAGTGGGGC
Stat3
Forward CCTCCAGACGGCAGCCA
Reverse TCATTTTCTGTTCTAGATCCTGCAC
Probe AGCAAGGGGGCCAGGCCAA
Mmp2
Forward TGCAGGAGACAAGTTCTGGAGAT
Reverse ACCCTTGAAGAAGTAGCTATGACCA
Probe CCGCCCTGCAGGTCCACGAC
Fasn
Forward CTTAGCAGAGATCCCGAGACG
Reverse GGTCCTTTGAAGTCGAAGAAGAA
Probe TGGGCTACAGCATGGTGGGCTG
Cpt1
Forward GGGCCATCTGTGGGAGTATG
Reverse CCTTTACAGTGTCCATTCCTGAGT
Probe TGGCCGACGTCTTCCAGC
Cycs
Forward GGACCAAATCTCCACGGTCT
Reverse CCCCAGGTGATGCCTTTGT
Probe AGCCTGGCCTGTCTTCCGCCC
Ucp3
Forward ACTGACAACTTCCCCTGTCACTT
Reverse GCGTTCATGTATCGGGTCTTTA
Probe ACAGTGGTGGCCTCCCCGGTG
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dium selenite (Sigma-Aldrich), 100 mg/mL penicillin and
100 U/mL streptomycin (Gibco Invitrogen Corporation,
Paisley, Scotland), 3 g/L glucose (Sigma-Aldrich), and 26 IU/
L insulin (Novo Nordisk, Bagsværd, Denmark). Cells were
treated with 1000 nmol/L GalNAc-control ASO or GalNAc-
Stk25 ASO for 24 hours. To measure b-oxidation, cells were
incubated in the presence of (9,10-3H[N])-palmitic acid, and
(3H)-labeled water was measured as the product of free
fatty acid oxidation.9
Statistical Analysis
Statistical signiﬁcance between the groups was eval-
uated using the 2-sample Student t test, and among more
than 2 groups by 1-way analysis of variance followed by a
2-sample Student t test for post hoc analysis. The
Shapiro–Wilk test and the Levene test were applied to
conﬁrm the normality of distribution of residuals and the
homogeneity of variances, respectively. Differences were
considered statistically signiﬁcant at a P value less than.05. All statistical analyses were performed using SPSS
Statistics (v24; IBM Corporation, Armonk, NY).References
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